Soligenix Inc (SNGX)
NASDAQ:SNGX
Want to see SNGX full AI Analyst Report?
SNGX Stock Chart & Stats
$1.44
-$0.10(-2.65%)
At close: 4:00 PM EST
$1.44
-$0.10(-2.65%)
Day’s Range― - ―
52-Week Range$0.33 - $6.23
Previous CloseN/A
Volume55.16K
Average Volume (3M)293.55K
Market Cap
$3.48M
Enterprise Value-$4.09M
Total Cash (Recent Filing)$7.94M
Total Debt (Recent Filing)$358.14K
Price to Earnings (P/E)―
Beta0.32
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.32
Shares Outstanding10,306,079
10 Day Avg. Volume179,673
30 Day Avg. Volume293,551
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.68
Enterprise Value/Market Cap-1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.40K
Enterprise Value/Ebitda0.34
Forecast
1Y Price Target
$10.00Price Target Upside594.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.85
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Stronger Balance Sheet And Lower LeverageLeverage has materially improved with debt falling and equity turning positive, creating a firmer financial cushion. Lower debt reduces interest and refinancing pressure, improving strategic optionality for M&A or partnerships and lowering the structural risk of insolvency over the next 2–6 months.
Stable Funding Model Via Government And CollaborationsA business model anchored in government contracts, grants and collaborative payments provides relatively durable non-dilutive funding sources versus pure market sales. For a clinical-stage biotech, reliable contract/grant channels improve the ability to advance programs through clinical milestones without immediate product revenue.
Regulatory Incentives: Orphan Drug DesignationOrphan designation confers lasting regulatory benefits—potential fee waivers, protocol assistance, reduced trial size and market exclusivity—which strengthen commercial and partner interest for dusquetide and make development paths and future partnering or licensing more feasible over the medium term.
Bears Say
Pivotal Phase 3 Halted For FutilityA halted pivotal study is a durable, material setback: it undermines the lead asset's approval pathway, reduces near-term value drivers, and forces strategic reassessment. This increases the likelihood of needing to pivot programs, seek partners, or pursue M&A, and raises long-term funding and commercial risk.
High Cash Burn With Limited RunwayPersistently negative operating cash flow and rising burn create structural funding pressure. With operating cash outflows materially exceeding inflows, the company will likely need external capital or asset transactions in the coming months, increasing dilution risk and constraining strategic flexibility.
Minimal Revenue And Widening LossesAs a pre-commercial company with negligible product revenue and expanding net losses, Soligenix lacks internal earnings capacity to fund development. This structural deficit keeps the company dependent on external funding and elevates long-term execution risk until a product reaches commercialization.
Soligenix News
SNGX FAQ
What was Soligenix Inc’s price range in the past 12 months?
Soligenix Inc lowest stock price was $0.33 and its highest was $6.23 in the past 12 months.
What is Soligenix Inc’s market cap?
Soligenix Inc’s market cap is $3.48M.
When is Soligenix Inc’s upcoming earnings report date?
Soligenix Inc’s upcoming earnings report date is May 08, 2026 which is in 8 days.
How were Soligenix Inc’s earnings last quarter?
Soligenix Inc released its earnings results on Mar 31, 2026. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.6.
Is Soligenix Inc overvalued?
According to Wall Street analysts Soligenix Inc’s price is currently Undervalued.
Does Soligenix Inc pay dividends?
Soligenix Inc does not currently pay dividends.
What is Soligenix Inc’s EPS estimate?
Soligenix Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Soligenix Inc have?
Soligenix Inc has 10,306,079 shares outstanding.
What happened to Soligenix Inc’s price movement after its last earnings report?
Soligenix Inc reported an EPS of $0.32 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 6.306%.
Which hedge fund is a major shareholder of Soligenix Inc?
Currently, no hedge funds are holding shares in SNGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Soligenix Inc
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
SNGX Stock 12 Month Forecast
Average Price Target
$10.00
▲(594.44% Upside)
Technical Analysis
Ownership Overview
3.77% Insiders
1.04% Mutual Funds
<0.01% Other Institutional Investors
94.62% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---